Val-Bernal José-Fernando, Martino María, Romay Félix, Yllera Elena
Pathology Unit, Medical and Surgical Sciences Department, University of Cantabria and IDIVAL Research Institute, Santander, Spain.
Anatomical Pathology Service, Marqués de Valdecilla University Hospital, University of Cantabria and IDIVAL Research Institute, Santander, Spain.
Pathol Res Pract. 2018 Jul;214(7):949-956. doi: 10.1016/j.prp.2018.05.021. Epub 2018 May 22.
Evaluation of mediastinal lymphadenopathy in patients with a previous diagnosis of renal cell carcinoma (RCC) is critical for the determination of further treatment. A minimally invasive method of cytology sampling of mediastinal lymph nodes using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a useful tool in diagnosis. Between January 2010 and April 2018, we performed 1744 EBUS-TBNA studies of mediastinal and hilar lymph nodes for a variety of clinical indications including mediastinal malignancy. Sixteen patients (93.7% males, mean age 59.1 years, range 44-81 years) were diagnosed by cytological and cell block study to have metastatic clear cell RCC. Twelve patients had been diagnosed with clear cell RCC in the past (mean 39 months, range 4-89 months) while in four, the tumor was primarily diagnosed in the staging phase on the basis of EBUS-TBNA. The EBUS features of the mediastinal nodal masses included increase of size (mean 2.5 cm, range 1.6-3.8 cm), irregular, inhomogeneous, hypervascular, and hyperechoic echotexture. EBUS-TBNA is a procedure safe and effective for evaluating mediastinal lymphadenopathy in patients with clear cell RCC. Immunohistochemistry in the cell block is decisive for proper diagnosis. The cytologist plays a key role in the diagnosis of metastatic clear cell RCC due to the treatment implications that this neoplasm encompasses.
对于先前诊断为肾细胞癌(RCC)的患者,评估纵隔淋巴结肿大对于确定进一步治疗至关重要。一种使用支气管内超声引导经支气管针吸活检(EBUS-TBNA)对纵隔淋巴结进行细胞学采样的微创方法已成为诊断中的一种有用工具。在2010年1月至2018年4月期间,我们针对包括纵隔恶性肿瘤在内的各种临床指征,对纵隔和肺门淋巴结进行了1744次EBUS-TBNA研究。16例患者(男性占93.7%,平均年龄59.1岁,范围44 - 81岁)经细胞学和细胞块研究诊断为转移性透明细胞肾细胞癌。12例患者过去曾被诊断为透明细胞肾细胞癌(平均39个月,范围4 - 89个月),而另外4例患者的肿瘤主要是在分期阶段基于EBUS-TBNA首次诊断出来的。纵隔淋巴结肿块的EBUS特征包括大小增加(平均2.5厘米,范围1.6 - 3.8厘米)、形态不规则、回声不均匀、血管增多以及高回声纹理。EBUS-TBNA是评估透明细胞肾细胞癌患者纵隔淋巴结肿大的一种安全有效的方法。细胞块中的免疫组织化学对于准确诊断具有决定性作用。由于这种肿瘤所涉及的治疗意义,细胞病理学家在转移性透明细胞肾细胞癌的诊断中起着关键作用。